Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the relative bioequivalency study of dosage forms of Clemastine 2.68 mg tablets.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories) |
|
| 2 | Experimental | Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories) | Drug |
| ||
| Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.) |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence based on AUC and Cmax | 19 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| James C. Kisicki, M.D. | Harris Laboratories, Incorporated | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D006967 | Hypersensitivity |
| ID | Term |
|---|---|
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D002974 | Clemastine |
| ID | Term |
|---|---|
| D011759 | Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|